Evidence signal01
There is a historical human-study record
Emideltide was not evaluated from a blank slate. FDA reviewed older human sleep, narcolepsy and withdrawal literature.
FDA briefing pp. 23–40Day 2 recordPCAC unfavorable
Peptide dossier / July 23–24, 2026Emideltide (DSIP)
Older human studies did not establish the nominated subcutaneous use.
Emideltide had older human studies, but the record was small, methodologically uneven and largely intravenous rather than the nominated subcutaneous route.
Decision boundaryPCAC advice is not FDA approval, does not establish safety or effectiveness, and did not itself place either form on the 503A Bulks List.
Editorial review
Analysis
FDA staff and PCAC both opposed inclusion of both forms.
Decisive limitation02
The evidence did not transfer cleanly to modern SC compounding
The exact chemical form was often unclear, the studies were small and methodologically limited, and the nominated subcutaneous route lacked direct effectiveness evidence.
FDA briefing pp. 30–40, 52–55PeptideBase read
The committee outcome belongs beside the evidence record—not on top of it. A favorable advisory vote describes the panel’s recommendation on compounding eligibility; it does not erase FDA’s characterization, route-match or human-evidence concerns.
The case made in the room
Testimony
These are attributed testimony arguments, not PeptideBase endorsements. Each one is paired with the most relevant FDA answer and an explicit assessment of what the evidence can—and cannot—carry.
3published speaker moments
Only named speaker moments reconciled against a word-timestamped machine transcript of the official recording appear here. The method is two-pass transcript reconciliation: both passes read that same transcript, so this is not audio review and not independent primary-source confirmation. Where the two passes disagreed about who was speaking, the moment was withheld rather than published. Statements remain attributed arguments unless the underlying evidence was independently established from a named source outside the hearing record, and each moment carries its own disclosed limitations.
01Supports listing
Alex Tatem, MD
Board-certified urologist, private practice, Indianapolis
Verify credentialsAttributed testimony
The historical-clinical case
Tatem made a historical-clinical case: the 1970s Basel discovery work, a 1981 Lancet report, and a 1984 series of 107 patients in opioid withdrawal. The studies he described are small and historical, and the testimony did not turn them into modern evidence for the nominated subcutaneous form and uses.
What is not established
- Automatic speech recognition renders the surname 'Tatum' throughout; the site displays the correct spelling, 'Tatem'. This is a transcription artefact, not an unresolved identity — the speaker is independently identified at the linked practice profile.
- Both identity cues are present, but the moderator’s naming is garbled to "Dr. Taren" — a second utterance, not a clean name match.
Emideltide session public comment · attributed argument, not an established factTranscript-reconciled — second review passedPlay the source01:36:22–01:40:16
Attributed testimony
The insufficient-evidence objection
Hertig asked the committee to vote no on adding the substance to the 503A bulks list. He argued that the supporting study is more than thirty years old and that the evidence does not support safety or effectiveness, which he treated as decisive given that a listing decision is binary and hard to reverse. He allowed that benefits may exist, and said they should be established through research rather than through listing.
What is not established
- Automatic speech recognition renders the surname inconsistently across sessions, with a differing consonant in half. The spelling shown here is confirmed independently of the transcript by Wired's coverage of this hearing, which names him and his organisation. The variation is a transcription artefact, not an unresolved identity.
- His closing request is paraphrased rather than quoted: the transcript garbles "bulks list" to "ALCS list" at that exact position, so no span here is reproducible word-for-word.
Emideltide session public comment · attributed argument, not an established factTranscript-reconciled — second review passedPlay the source01:19:46–01:22:40
03Opposes listing
Peter Lurie, MD, MPH
President and Executive Director, Center for Science in the Public Interest; former FDA Associate Commissioner
Verify credentialsAttributed testimony
The hearing-wide case against all seven
Lurie said CSPI opposed adding all seven substances, for three reasons: that listing would be inconsistent with FDA’s own compounding standards, that compounded products pose distinct consumer risks, and that listing would remove incentives to develop products through the standard drug-approval pathway.
What is not established
- Identity rests on a self-introduction plus the chair’s sequential numbering ("speaker number three"), not on the chair speaking his name.
BPC-157 session public comment, speaker #3 · explicitly applied to all seven substancesTranscript-reconciled — second review passedPlay the source00:57:02–00:59:43
Historical sleep and withdrawal studies provide clinical evidence for emideltide.
Historical small studiesWhat supports it
The hearing cited older, small studies. Their identity, methods, exact material and relationship to the nominated subcutaneous use were not fully resolved in the reviewed record.
FDA’s answer
FDA found no adequate study supporting effectiveness for the nominated uses and no safety data for the proposed subcutaneous route.
FDA Day 2 presentation · 02:19:28PeptideBase assessment
Older studies are a lead worth locating and reappraising. They are not enough to establish modern effectiveness or subcutaneous safety.
Why the judgments diverged
This was the one subject on which the two judgments aligned.
Historical studies and access arguments did not overcome the record’s unresolved effectiveness, route and safety problems. The committee majority recommended against both forms, consistent with FDA staff’s position.
Record synthesis; no divergence occurred for this subjectClaim versus record
Claim checks
These are recurring propositions in the wider peptide discussion, not attributed speaker quotations.
Recurring claim
Older intravenous sleep studies establish the nominated subcutaneous use.
Official record
FDA found no effectiveness study using the nominated SC route for chronic insomnia; the available clinical data it located used intravenous administration.
What it does not establish
FDA briefing pp. 23–31Evidence from one route cannot be assumed to establish exposure, effectiveness or safety for another route.
Recurring claim
The historical clinical record is robust across insomnia, narcolepsy and withdrawal.
Official record
FDA described small and methodologically limited studies; the narcolepsy evidence included a single-subject case report, and withdrawal studies lacked key controls or randomization.
What it does not establish
FDA briefing pp. 30–40, 52–55Historical use can be relevant, but weak design, small samples, subjective endpoints and uncertain chemical form restrict what the studies establish.
Evidence architecture
Evidence
“Absent” means FDA said it did not identify that evidence within this evaluation. It is not a universal claim that no evidence exists anywhere.
| Evidence question | Status | FDA-record summary | Locator |
|---|---|---|---|
| Human clinical evidence | limited | FDA-record summaryOlder small IV studies and a single-subject narcolepsy report were identified. | LocatorBriefing pp. 23–40 |
| Nonclinical evidence | indirect | FDA-record summaryPreclinical sleep-related material existed but did not resolve the nominated human uses. | LocatorBriefing pp. 40–48 |
| Exact-form match | unresolved | FDA-record summaryFDA reported that content testing in the certificate of analysis referred to emideltide acetate while the clinical references in the nomination referred to emideltide (free base), and that “it is unclear whether emideltide or emideltide acetate was intended to be the nominated BDS based on the information provided.” | LocatorBriefing pp. 8–19, 22–23 |
| Nominated-route match | absent | FDA-record summaryFDA identified no effectiveness study using the nominated SC route. | LocatorBriefing p. 30 |
| Evaluated-use match | limited | FDA-record summaryThe record touched all three uses, but methods, samples and consistency were inadequate. | LocatorBriefing pp. 23–40 |
| Product characterization | not well characterized | FDA-record summaryFDA concluded that “emideltide (free base) is considered not well-characterized from the physical and chemical characterization perspective”; the same conclusion is stated for emideltide acetate. Impurity, aggregation and endotoxin gaps were identified. | LocatorBriefing pp. 8–19 |
| Human safety | limited | FDA-record summarySmall IV studies reported some adverse effects, including hypotension in withdrawal studies; SC safety was not established. | LocatorBriefing pp. 48–55 |
| Historical compounding use | limited | FDA-record summaryFDA found published and market information too limited to characterize historical compounding use. | LocatorBriefing pp. 20–22 |
Qualitative evidence map · no numerical score · scoped to FDA’s July 2026 evaluation
FDA findings
Five parts of the staff case.
01characterizationBoth emideltide free base and emideltide acetate were considered not well characterized.Day 2 pp. 38, 41
02:10:2402effectivenessFDA found no adequate study supporting effectiveness for the nominated uses.Day 2 pp. 48–54
02:19:2803safetyFDA found no safety data for the proposed subcutaneous route and insufficient information for the nominated uses.Day 2 pp. 55–62
02:30:0804historical useFDA found the extent of historical use in compounding unclear.Day 2 pp. 63–67
02:32:4205recommendationFDA proposed that neither emideltide free base nor emideltide acetate be included on the 503A Bulks List.Day 2 pp. 67–68
02:34:07
02:10:2402effectivenessFDA found no adequate study supporting effectiveness for the nominated uses.Day 2 pp. 48–54
02:19:2803safetyFDA found no safety data for the proposed subcutaneous route and insufficient information for the nominated uses.Day 2 pp. 55–62
02:30:0804historical useFDA found the extent of historical use in compounding unclear.Day 2 pp. 63–67
02:32:4205recommendationFDA proposed that neither emideltide free base nor emideltide acetate be included on the 503A Bulks List.Day 2 pp. 67–68
02:34:07
What changes the assessment
Sources
A useful dossier should show the reader what evidence could materially strengthen or weaken the current read.
01
Modern controlled trials using the exact form, SC route and nominated uses
02
Validated impurity, aggregate, endotoxin and finished-product specifications
03
Dose-related cardiovascular and hypotension safety evidence
Decision boundaryPCAC advice is not FDA approval, does not establish safety or effectiveness, and did not itself place either form on the 503A Bulks List.
Continue the record
View all sevenRelated peptide dossiers
Day 2
Epitalon
The official record contained circadian and melatonin-related findings, but no direct insomnia trial using the nominated SC product and no clinical safety record.
Open dossierDay 2Semax
Semax had a wider pharmacology literature and limited clinical references, but FDA found the direct clinical record too small and methodologically weak for the nominated uses.
Open dossier